Gilead Seeking FDA Approval For Investigational Long-Acting HIV Treatment Lenacapavir

Healio (7/6, Downey) reports, “Gilead Sciences submitted a new drug application to the FDA for the approval of lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor that is given subcutaneously every 6 months.” Key six-month data for the dru...